J&J 2Q profit climbs 13 percent on new-drug sales - 13 WTHR Indianapolis

J&J 2Q profit climbs 13 percent on new-drug sales

Posted: Updated:
(AP Photo/Chris O'Meara, File). FILE - This Oct. 16 2012, file photo, shows Johnson and Johnson products, including Band Aid brand adhesive bandages, arranged for a photo in St. (AP Photo/Chris O'Meara, File). FILE - This Oct. 16 2012, file photo, shows Johnson and Johnson products, including Band Aid brand adhesive bandages, arranged for a photo in St.
  • NationalMore>>

  • Family feud sparks revolt at grocery store chain

    Family feud sparks revolt at grocery store chain

    Friday, July 25 2014 9:03 PM EDT2014-07-26 01:03:38 GMT
    It's been called a David vs. Goliath story, a "Tale of Two Arthurs" and even the "ultimate Greek tragedy," but the characters in this drama are not Biblical or literary figures.More >>
    It's been called a David vs. Goliath story, a "Tale of Two Arthurs" and even the "ultimate Greek tragedy," but the characters in this drama are not Biblical or literary figures. They're grocery store owners.More >>
  • Arizona's McCain: Execution was torture

    Arizona's McCain: Execution was torture

    Friday, July 25 2014 9:03 PM EDT2014-07-26 01:03:02 GMT
    U.S. District Judge Neil V. Wake was attending a ceremony for a judicial colleague when he received an urgent - and unusual - request: Lawyers for a condemned inmate wanted him to stop an execution that didn't...More >>
    U.S. Sen. John McCain says the execution of an Arizona inmate that lasted two hours was torture.More >>
  • Carjacked SUV hits crowd, killing 3 young siblings

    Carjacked SUV hits crowd, killing 3 young siblings

    Friday, July 25 2014 8:44 PM EDT2014-07-26 00:44:45 GMT
    Two men forced a woman into the backseat of her vehicle at gunpoint, drove off but later lost control and plowed into a group of people on a corner near a fruit stand in Philadelphia on Friday, police said. Two...More >>
    Two men carjacked a woman at gunpoint but soon sped out of control, killing three children Friday as they plowed into a group selling fruit to raise money for their church, Philadelphia police said.More >>
By BY LINDA A. JOHNSON
AP Business Writer

Strong sales of several new drugs, particularly its hot new hepatitis medicine, lifted Johnson & Johnson's second-quarter profit by 13 percent, topping analysts' expectations.

The world's biggest maker of health care products raised its 2014 profit forecast for the second time since January, again up by a nickel to a new range of $5.85 to $5.92 per share, excluding one-time items.

Still, J&J shares fell in midday trading after company officials cited two drags on second-half revenue: the June 30 sale of its Ortho-Clinical Diagnostics business for about $4 billion, and expected new competition for Olysio, J&J's new treatment for chronic hepatitis C. In midday trading, shares were down $1.71, or 1.6 percent, at $103.67.

J&J on Tuesday reported earnings increased to $4.33 billion, or $1.51 per share, from $3.83 billion, or $1.33 per share, a year earlier.

Earnings, adjusted for non-recurring litigation and other costs, came to $1.66 per share. Analysts surveyed by Zacks Investment Research expected $1.54 per share, on average.

The maker of Band-Aids, medical devices and biologic drugs said revenue rose 9.1 percent to $19.5 billion from $17.88 billion a year ago. Analysts expected $18.85 billion.

The company "seems to have turned the corner on its string of unpleasant surprises, and is delivering mostly positive surprises," said Erik Gordon, a professor and analyst at University of Michigan's Ross School of Business.

The New Brunswick, New Jersey-based company said prescription drug sales rose 21 percent to $8.51 billion. That was led by Olysio, at $831 million in the quarter, as well as Xarelto for preventing heart attacks and strokes ($361 million) and Zytiga for prostate cancer ($562 million). J&J's two newer drugs for rheumatoid arthritis and other immune system disorders, Simponi and Stelara, both grew by more than 40 percent, lifting the immunology franchise to $2.63 billion in total sales.

J&J CEO Alex Gorsky said J&J plans to apply for approval of 10 new drugs, plus 15 additional uses for existing medicines, through 2017.

The strong performance of prescription drugs recently has helped it regain the lead over J&J's device business and offset the lagging consumer segment, which is still recovering from dozens of product recalls since 2009.

Most of J&J's nonprescription medicines, including Tylenol, Motrin and Benadryl, are now back in stores, boosting their total sales nearly 8 percent to $1 billion. Consumer product sales increased 2.4 percent to a total of $3.74 billion.

Medical device sales edged up 0.7 percent to $7.24 billion.

Johnson & Johnson shares have increased $13.27, or 15 percent, in the last 12 months.

___

Follow Linda A. Johnson at www.twitter.com/LindaJ_onPharma

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Powered by WorldNow